%0 Journal Article
%T 肝癌的过继性细胞免疫治疗应用的进展研究<br>Research Progress of Adoptive Cellular Immunotherapy for the Treatment of Hepatocellular Carcinoma
%A 陈蓁臻
%A 张爱绮
%A 龚建平
%J Advances in Clinical Medicine
%P 2710-2715
%@ 2161-8720
%D 2020
%I Hans Publishing
%R 10.12677/ACM.2020.1011412
%X <div style=\"text-align:justify;\">
	肝细胞肝癌是世界上最常见的恶性肿瘤之一，主要的治疗方式包括手术切除、射频消融、经导管动脉化疗栓塞术(Transarterial chemoembolization, TACE)、放化疗等。目前还有各种相关抗肿瘤的免疫治疗，广泛研究的免疫细胞主要有：树突状细胞(DC)、细胞因子诱导杀伤细胞(CIK)、共培养免疫细胞(DC-CIK)、嵌合抗原受体T细胞(CAR-T)等。治疗措施的选择取决于肿瘤阶段、大小及其肿瘤微环境状态。本文就过继性免疫细胞疗法在肝癌临床治疗中的应用作一综述。<br />
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The main treatment methods include surgical resection, radiofrequency ablation, TACE, chemoradiotherapy and so on. At present, there are a variety of anti-tumor immunotherapies. The immune cells extensively studied include dendritic cells (DC), cytokine induced killer cells (CIK), co-cultured immune cells (DC-CIK), chimeric antigen receptor T cells (CAR-T), etc. The choice of treatment depends on the tumor stage, size, and tumor microenvironmental status. This article reviews the application of adoptive immune cell therapy in the clinical treatment of liver cancer.
</div>
%K 肝癌，免疫细胞，过继治疗，综述<br>Hepatocellular Carcinoma
%K Immune Cells
%K Adoptive Therapy
%K Review
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=38819